Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE ®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart ...
UAB Medicine offers liver transplantation as a treatment for metastatic colorectal cancer, expanding access to advanced ...
Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...
SurvivorNet on MSN
New drug combination shows promise in advanced colorectal cancer: The question now is when to use it
A two-drug combination (zanzalintinib plus atezolizumab) improved survival for metastatic colon cancer patients who already ...
Cytovation inks agreement with BeOne Medicines to evaluate getacatetide in combo with tislelizumab in colorectal cancer: Bergen, Norway Thursday, May 21, 2026, 17:00 Hrs [IST] Cyt ...
The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine–tipiracil. MSI-H : Microsatellite instability High. dMMR : Mismatch repair deficient. RCT : Randomised ...
The University of Alabama at Birmingham Division of Transplantation now offers liver transplantation for patients with ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply ...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results